IFRS vs US GAAP: Key Differences Every Business and Finance Professional Must Know

The differences that move numbers — inventory, leases, development costs, impairment and investment property — and what each one does to ratios, analyst adjustments and cross-border deals.

A pharmaceutical company in Germany developing a new drug and a pharmaceutical company in New Jersey developing the same drug — same science, same investment, same commercial prospects — can report dramatically different financial statements if one follows IFRS and the other follows US GAAP. The German company, under IAS 38, is required to capitalise development costs once feasibility is established; the New Jersey company, under ASC 730, expenses them as incurred. Same economic reality, different accounting — and the difference affects not just net income but assets, equity, and every ratio built on those numbers.

This is what IFRS vs US GAAP differences mean in practice: they are not abstract standard-setting debates but concrete differences in reported numbers that affect how companies look to investors, how they compare to peers, how financial covenants are structured, and how cross-border transactions are negotiated. Decades of convergence work between the IASB and FASB has aligned the two frameworks significantly — particularly on revenue recognition and lease accounting — but significant gaps remain in inventory, development costs, investment property, impairment, and the treatment of certain financial instruments.

This article takes a practitioner's approach: starting with a complete reference table of differences that move numbers, then examining the most impactful areas in depth, with specific attention to what the difference means for financial ratios, analyst adjustments, and cross-border transactions. Indian businesses operating internationally, finance professionals working across jurisdictions, and accounting advisors serving multinational clients will find this guide directly applicable to their daily work.

IFRS vs US GAAP — Practitioner Quick-Reference: Which Differences Move Numbers?

The table below focuses exclusively on differences that have a material impact on reported financial statements. IFRS columns are shaded green; US GAAP columns are shaded red. Areas of alignment are shown in the impact column.

Three observations from the table above. First, the differences cluster in specific areas — inventory valuation, asset measurement, and the capitalisation vs expense decision. Second, some historical differences (extraordinary items) have been eliminated and the frameworks have converged. Third, the impact on financial ratios can be dramatic — a company with significant R&D spending, real estate holdings, or long-term leases may look fundamentally different under IFRS vs GAAP.

What Is the Foundational Difference Between IFRS and US GAAP — Principles vs Rules?

Every individual accounting difference between IFRS and US GAAP flows from a foundational philosophical difference in how the two frameworks approach standard-setting. This distinction shapes not just specific treatments but how practitioners think about novel transactions and edge cases.

IFRS: Principles-Based

IFRS is built on a conceptual framework that articulates qualitative characteristics of useful financial information — relevance, faithful representation, comparability, verifiability, timeliness, and understandability. Individual standards are designed to achieve these objectives in specific areas, but they rely heavily on professional judgment. When a transaction is unusual or not explicitly covered, an IFRS preparer asks: what treatment best achieves a fair presentation of the economic substance?

This approach produces flexibility and adaptability — IFRS can accommodate novel transactions without a specific rule for every situation. But it also means two companies facing the same facts may account for them differently, both correctly, because both can justify their judgment. Comparability within a jurisdiction is sometimes lower under IFRS than under GAAP.

US GAAP: Rules-Based

US GAAP, developed through decades of SEC enforcement and FASB standard-setting, has accumulated an enormous body of detailed, prescriptive guidance. The FASB Accounting Standards Codification (ASC) contains industry-specific guidance, transaction-specific rules, and worked examples that tell preparers exactly how to account for most situations. When a transaction falls under a specific rule, preparers apply the rule — judgment is less central.

This approach produces greater comparability within the US market and reduces the scope for earnings management through creative judgment. But it can also produce outcomes that appear technically compliant but economically misleading — the LIFO inventory method being a classic example, where mechanical application of a permissible accounting method produces balance sheet inventory values that bear little relationship to current cost or value.

Which Standard Applies to Your Business — IFRS or US GAAP?

The answer depends on where you are listed, where you are incorporated, and what your stakeholders require. The table below provides a practical reference.

For Indian businesses, the relevant framework is Ind AS — India's IFRS-converged standards — which are mandatory for listed companies and large unlisted companies. Ind AS is substantially aligned with IFRS but has specific carve-outs. Indian subsidiaries of US multinationals are the most common situation requiring dual reporting: they prepare Ind AS financial statements for MCA compliance and provide US GAAP data for their parent's consolidated statements. The reconciliation between Ind AS and US GAAP is typically more complex than the reconciliation between Ind AS and IFRS, because US GAAP differences are broader. Getting both sets right starts with disciplined financial statement preparation.

Why Does LIFO Inventory Accounting Create the Biggest Comparability Problem?

No single accounting difference between IFRS and US GAAP creates more comparability problems than the LIFO (Last-In, First-Out) inventory method. Under IAS 2 (IFRS), LIFO is explicitly prohibited. Under ASC 330 (US GAAP), LIFO is permitted alongside FIFO and weighted average cost.

The implications of LIFO in an inflationary environment are significant and well-documented. When prices are rising, LIFO assumes the most recently purchased (higher-cost) inventory is sold first — producing a higher cost of goods sold, lower gross profit, and lower taxable income than FIFO. Simultaneously, the balance sheet shows inventory at old, lower-cost layers — the "LIFO reserve" represents the cumulative gap between LIFO and FIFO inventory values.

When a US GAAP company with a significant LIFO reserve is compared to an IFRS-reporting competitor on the same gross margin or return on assets basis, the comparison is fundamentally flawed unless the LIFO reserve is adjusted. Most US GAAP companies disclose their LIFO reserve in the notes, allowing analysts to add it back to inventory to produce a FIFO-equivalent (and therefore IFRS-comparable) balance sheet.

The LIFO method is permitted under US GAAP primarily for tax reasons — the US Internal Revenue Code permits LIFO for tax purposes, and the tax conformity requirement means that any company that uses LIFO for tax purposes must also use it for financial reporting. IFRS's prohibition is based on faithful representation: LIFO does not reflect the actual physical flow of inventory in most businesses (goods are not literally consumed in reverse order of purchase) and produces a balance sheet figure that can be significantly understated in periods of sustained inflation.

How Do Development Costs Produce Different Balance Sheets for R&D Companies?

The treatment of development costs is one of the most consequential differences between IFRS and US GAAP for technology, pharmaceutical, biotech, and any R&D-intensive company. The frameworks start from opposite positions and arrive at very different balance sheets.

IFRS Position: IAS 38 — Capitalise When Ready

IAS 38 (Intangible Assets) draws a clear distinction between research and development. Research costs — early-stage investigation with no certainty of commercial outcome — are expensed as incurred. Development costs — the application of research findings to a plan for production of new or improved products — must be capitalised when all six criteria under IAS 38.57 are met:

1. Technical feasibility. The technical capability to complete the asset exists.
2. Intention. Management intends to complete the development and use or sell the asset.
3. Ability. The entity has the ability to use or sell the intangible asset.
4. Economic benefits. The asset will generate probable future economic benefits — a market exists or the asset will be used internally.
5. Adequate resources. Technical, financial, and other resources to complete the development are available.
6. Reliable measurement. Expenditure attributable to the asset during development can be reliably measured.

When all six criteria are met — typically in later-stage pharmaceutical development, software development past proof-of-concept, or industrial product development post-prototype — the costs are capitalised as an intangible asset and amortised over the expected useful life once the asset becomes available for use.

US GAAP Position: ASC 730 — Expense Everything (With One Exception)

Under ASC 730, all research and development costs are expensed as incurred — no assessment of feasibility or probable future benefits changes this. The one exception is internal-use computer software, where ASC 350-40 requires capitalisation of costs in the application development stage (between preliminary project stage and post-implementation stage). Even here, the application is narrower than IAS 38's broader development cost capitalisation.

The result for a pharma company in Phase III clinical trials: under IFRS, if the six IAS 38 criteria are met, significant Phase III costs are capitalised — the balance sheet shows a large intangible asset, R&D expense is lower, profit is higher. Under GAAP, all Phase III costs are expensed — no intangible, higher R&D expense, lower profit. Same drug, same trials, same economic reality — materially different financial statements. This affects every ratio: P/E (GAAP shows lower earnings, so P/E looks higher), asset turnover (IFRS shows more assets), R&D intensity as % of revenue (GAAP shows higher).

Are IFRS 15 and ASC 606 Fully Aligned on Revenue Recognition?

Revenue recognition was the landmark IASB-FASB joint project, completed in 2014. Both frameworks adopted the same five-step model and both became effective for most companies in 2018. The level of convergence is high — higher than in almost any other area. But differences remain in specific applications.

The practical message from the revenue table: for most businesses, IFRS 15 and ASC 606 produce the same answer. The differences that remain are concentrated in technology (IP licences), media (content licences, royalties), and complex services with variable consideration. For M&A due diligence involving a US GAAP company being acquired by an IFRS-reporting buyer, revenue policies should be reviewed specifically for licence and variable consideration treatments — these are the most likely areas to find differences that require adjustment. Our cross-border M&A financial advisory work starts with exactly this review.

Why Do IFRS 16 and ASC 842 Produce Different EBITDAs for the Same Lease?

Lease accounting reform was the other major IASB-FASB joint project, completing with IFRS 16 (effective 2019) and ASC 842 (effective 2019 for public companies). Both frameworks put most leases on the balance sheet — this is the big change from their predecessors. But they diverge in a critical area: income statement treatment of what ASC 842 calls "operating leases."

The EBITDA difference is the most practically important for M&A, credit analysis, and peer comparison. Consider a retail company with 100 stores, each with a 10-year operating lease at ₹10 lakh per year. Under IFRS 16: EBITDA increases by ₹1,000 lakh (lease cost moves below EBIT as depreciation + interest); EBIT is lower in early years. Under ASC 842: EBITDA increases less — the ₹1,000 lakh straight-line cost stays in operating expenses above EBIT. When comparing this retailer to an IFRS-reporting peer, the EBITDA difference is not a business performance difference — it is a lease accounting methodology difference. Investment bankers, credit analysts, and M&A advisors must adjust for this when running cross-border comparisons or building enterprise value models.

How Does the One-Step vs Two-Step Impairment Test Change When Losses Are Recognised?

Impairment testing is an area where the foundational difference between IFRS's one-step test and US GAAP's historically two-step approach has important timing consequences — even though the US GAAP framework has been simplified in recent years.

IFRS: IAS 36 — One-Step Impairment Test

Under IAS 36, when there are indicators of impairment, the carrying amount of the asset (or cash-generating unit) is compared directly to its recoverable amount — the higher of fair value less costs of disposal and value in use (present value of expected future cash flows). If carrying amount exceeds recoverable amount, the excess is recognised immediately as an impairment loss. There is no preliminary screen — the test goes directly to the fair value / value in use comparison.

US GAAP: ASC 360 — Recoverability Screen First

Under ASC 360 for long-lived assets, impairment testing has historically been a two-step process. Step 1 asks: is the carrying amount greater than the sum of undiscounted future cash flows expected from the asset's use and eventual disposal? Only if Step 1 fails (i.e., undiscounted cash flows are less than carrying amount) does Step 2 occur — measuring the impairment loss as the excess of carrying amount over fair value. For goodwill, ASU 2017-04 eliminated Step 2, moving goodwill impairment to a single-step test similar to IFRS.

The critical consequence: an asset's value in use on a discounted basis can be below its carrying amount (triggering IFRS impairment) while the undiscounted cash flows are still above carrying amount (passing the GAAP recoverability screen and avoiding impairment recognition). GAAP's undiscounted screen acts as a buffer — assets that are technically impaired on an economic (discounted) basis may not trigger a write-down under GAAP. IFRS writes down sooner; GAAP sometimes delays.

The reversal difference adds another layer: IAS 36 requires reversal of an impairment loss (except goodwill) when circumstances change and the asset's recoverable amount increases above its carrying amount. ASC 360 does not permit reversal — once an asset is written down, the written-down amount becomes the new cost basis permanently. IFRS balance sheets therefore reflect recovered asset values; GAAP balance sheets carry permanent write-downs. Impairment judgments are among the first areas a statutory auditor tests, so align them early with your audit and assurance team.

Why Is PPE Revaluation an Accounting Policy Option That Only Exists Under IFRS?

One of the more significant structural differences between IFRS and US GAAP for asset-intensive businesses is the revaluation model for Property, Plant and Equipment (PPE). Under IAS 16 (IFRS), an entity may choose between two accounting policies for PPE: the cost model (historical cost less accumulated depreciation) or the revaluation model (carrying amount equals fair value at revaluation date, revaluation surplus in OCI). Under US GAAP, no revaluation model exists — PPE is always at historical cost less accumulated depreciation.

When an IFRS company elects the revaluation model for a class of PPE, upward revaluations create a revaluation surplus in other comprehensive income (OCI) — an equity reserve that does not affect P&L. Subsequent downward revaluations first reduce the revaluation surplus (in OCI) before hitting P&L. Depreciation is based on the revalued amount, so a revalued asset produces higher depreciation charges than the same asset on the cost model.

The comparison consequence: an IFRS company that revalues its property portfolio shows current market values in its balance sheet, while a US GAAP peer shows historical cost. For companies holding long-lived industrial assets, infrastructure, or real estate as PPE (as opposed to investment property), the balance sheet divergence can be substantial. Book value per share, price-to-book ratios, return on assets, and net asset value calculations are all affected.

Why Do Two Global Accounting Standards Still Exist?

The persistence of two separate major accounting frameworks after decades of convergence efforts is not an accident or oversight — it reflects deep structural differences in the political economy of standard-setting, the role of the SEC in US financial markets, and the genuine difficulty of reconciling principles-based and rules-based philosophies at the level of detailed implementation.

• 2001 — The IASB Is CreatedThe IASB was created as the successor to the International Accounting Standards Committee (IASC), with an explicit mission to develop a single set of high-quality global accounting standards.
• 2002 — The Norwalk AgreementThe IASB and FASB committed to convergence — eliminating unnecessary differences and developing jointly when possible.
• 2008–2016 — Landmark Joint ProjectsFor more than a decade the convergence agenda produced joint work on business combinations (2008), financial instruments (IAS 39/ASC 815 and later IFRS 9/ASC 326), revenue recognition (IFRS 15/ASC 606 in 2014), and leases (IFRS 16/ASC 842 in 2016).
• 2012 — The SEC Final Staff ReportThe SEC concluded that full IFRS adoption for US public companies was not appropriate at that time — citing concerns about IASB funding, governance, investor education, and the loss of US regulatory control over accounting standards.
• Since Then — Independent DevelopmentThe convergence agenda has formally wound down. Both bodies continue to monitor each other's work and consult on major projects, but they now develop independently. New IFRS standards — IFRS 17 on insurance contracts, amendments to IFRS 9, and sustainability reporting standards under IFRS S1/S2 — may or may not be adopted in the US under equivalent ASC topics.

The result is that finance professionals working across borders — M&A advisors, fund managers, credit analysts, CFOs of multinationals — must maintain working knowledge of both frameworks. N D Savla & Associates supports clients navigating all dimensions of the IFRS vs US GAAP distinction, from due diligence adjustments to dual GAAP reporting frameworks to investor presentation analytics.

What Do Finance Teams Ask Most About IFRS vs US GAAP?

These are the questions businesses and finance professionals raise most often when working across the two frameworks.